Dezca contains Deflazacort. Dezca uses:
|Manufacturer:||ARROWS 2 PHARMACEUTICALS|
|Last Updated:||2020-11-20 18:15:00|
Dezca contains Deflazacort 30.0 Mg. Dezca doses
Alternate day administration may be appropriate. Doses of Dezca usually lie in the range 0.25-1.5 mg/kg/day. The following ranges provide general guidance:
After administration occasionally GI disturbances like dyspepsia, nausea; musculoskeletal disorders like myopathy; depressed mood, skin atrophy, acne etc. may occur.
Dezca provides anti-inflammatory action by inhibiting Phospholipase A2 enzyme which is responsible for prostaglandin synthesis. Besides Dezca decreases the release of certain chemicals that are important in the immune system. By decreasing the release of these chemicals Dezca provides immunosuppressive action.
The following clinical conditions require special caution and frequent patient monitoring is necessary: Adrenal suppression and infection, child, adolescents, elderly, history of TB and steroid myopathy, hypertension, recent myocardial infarction, congestive heart failure, liver failure, renal impairment, diabetes mellitus and glaucoma (including family history), osteoporosis, corneal perforation, epilepsy, peptic ulcer, hypothyroidism, pregnancy and lactation.
Dezca is metabolized in the liver. It is recommended to increase the maintenance dose of Dezca if drugs which are liver enzyme inducers are co-administered, e.g. rifampicin, rifabutin, carbamazepine, phenobarbitone, phenytoin, primidone and aminoglutethimide. For drugs which inhibit liver enzymes, (e.g. ketoconazole) it may be possible to reduce the maintenance dose of Dezca.
Use in pregnancy: Dezca does cross the placenta. When administered for prolonged periods or repeatedly during pregnancy, corticosteroids may increase the risk of intra-uterine growth retardation. As with all drugs, corticosteroids should only be prescribed when the benefits to the mother and child outweigh the risks.
Use in lactation: Corticosteroids are excreted in breast milk. Doses up to 50 mg daily of Dezca are unlikely to cause systemic effects in the infant.
Hypersensitivity to or any of the ingredients. Patients receiving live virus immunisation.
Elderly: In elderly patients, no special precautions other than those usually adopted in patients receiving glucocorticoid therapy are necessary.
Hepatic impairment: In patients with hepatic impairment, blood levels of Dezca may be increased. Therefore the dose of Dezca should be carefully monitored and adjusted to the minimum effective dose.
Renal impairment: In renal impaired patients, no special precautions other than those usually adopted in patients receiving glucocorticoid therapy are necessary.
In patients who have received more than physiological doses of systemic corticosteroids (approximately 9mg per day or equivalent) for greater than 3 weeks, withdrawal should not be abrupt. How dose reduction should becarried out depends largely on whether the disease is likely to relapse as the dose of systemic corticosteroids is reduced.
Store in a cool (below 25° C.) and dry place , protected from light & moisture. Keep out of the reach of children.
Dezca Tablet price in India 312.8